Utility Score Can Help Predict Mortality in ICU Patients

Share this content:
Utility Score Can Help Predict Mortality in ICU Patients
Utility Score Can Help Predict Mortality in ICU Patients

(HealthDay News) -- A utility score can help predict poor outcome and survival among patients in the intensive care unit (ICU), according to a study published online May 26 in the Annals of the American Thoracic Society.

Kurien Thomas, M.D., from the Christian Medical College in Vellore, India, and colleagues conducted a 12-month prospective study in a 24-bed medical ICU in India. Health care providers assessed daily the global "utility score" on a 0 to 1 Likert scale, with 0 indicating death/severe disability and 1 indicating cure/perfect health. The authors examined the sensitivity, specificity, and likelihood-ratios of "utility" in predicting ICU mortality. They generated receiver operating characteristic (ROC) curves in order to compare day-two utility with APACHE-II.

The researchers found that for a day-two utility score of ≤0.3, survival without disability was 8.3 percent, compared with 95.8 percent for a day-five score of >0.8 (P < 0.001). As utility values decreased, the likelihood-ratio to predict mortality increased and was highest for utility 0.2. The area under ROC curve was comparable for utility and APACHE-II. Utility did not influence willingness-to-pay by the caregiver, which was 53 percent of treatment cost. There was an inverted U-shaped relationship for willingness-to-pay by ICU doctor and utility.

"Further prospective studies are needed to optimize utilization of scarce ICU resources by identifying patients for appropriate step-down care using utility and willingness-to-pay," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths